Clinic
MVHS INC
MVHS INC was paid $77.80M by Medicaid between Jan 2018 and Dec 2024, across 507 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.
33Billing provider infoMVHS INC
UTICA, NY 13502
UTICA, NY 13502
33aNPI1205877172assigned 06/09/2006
33bProvider typeHearing and Speech Clinic/Center
28Total paid$77.80M
24GClaims1,252,868
24DCodes billed507
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hearing and Speech Clinic/Center providers in New York
Rank by total paid#1 of 12
Median peer was paid$69K
This provider vs. median1,123×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,988 | $2.41M | |
| 2019 | 73,953 | $4.63M | |
| 2020 | 159,569 | $9.98M | |
| 2021 | 188,409 | $11.81M | |
| 2022 | 211,188 | $13.76M | |
| 2023 | 244,184 | $15.08M | |
| 2024incomplete | 334,577 | $20.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 23,805 | 22,686 | $13.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.6% | 20,785 | 19,847 | $7.43M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.9% | 21,777 | 20,873 | $5.37M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.3% | 34,298 | 32,646 | $3.35M |
| D0999 | Unspecified diagnostic procedure, by report | 4.0% | 28,367 | 22,922 | $3.12M |
| 90999 | Dialysis (unlisted procedure)Unlisted dialysis procedure, inpatient or outpatient | 3.8% | 18,482 | 1,607 | $2.93M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 6,395 | 6,247 | $2.76M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.1% | 28,704 | 23,712 | $2.42M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 27,849 | 26,341 | $2.01M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 11,531 | 10,658 | $1.59M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 7,456 | 6,139 | $1.29M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 12,716 | 11,017 | $1.13M |
495 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 5,215 | $1.10M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 1,519 | $1.01M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 2,587 | $880K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 14,373 | $796K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 5,162 | $787K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15,468 | $767K |
| 0223U | <1% | 4,471 | $695K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,654 | $664K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,974 | $663K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,651 | $662K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,326 | $648K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,313 | $629K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 4,630 | $592K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,766 | $587K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,513 | $500K |
| 80053 | Comprehensive metabolic panel | <1% | 52,565 | $499K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,885 | $499K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,560 | $467K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,490 | $443K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,973 | $419K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,323 | $378K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,236 | $377K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,133 | $352K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 204 | $351K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 6,706 | $338K |
| 76830 | Ultrasound, transvaginal | <1% | 2,497 | $325K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,200 | $321K |
| 90837 | Psychotherapy session, about an hour | <1% | 2,470 | $305K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,296 | $274K |
| G0378 | Hospital observation service, per hour | <1% | 2,348 | $258K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 282 | $255K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 2,891 | $249K |
| 76642 | <1% | 2,431 | $246K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,933 | $236K |
| 76770 | <1% | 1,446 | $236K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,781 | $222K |
| 76801 | <1% | 1,871 | $214K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,742 | $214K |
| 86900 | <1% | 7,167 | $213K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,123 | $212K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,711 | $210K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,960 | $207K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,154 | $207K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,154 | $206K |
| 71250 | <1% | 1,069 | $196K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,702 | $193K |
| 36415 | Collection of venous blood by venipuncture | <1% | 74,134 | $188K |
| 77066 | Tomosynthesis, mammo | <1% | 1,578 | $187K |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 4,236 | $179K |
| 93971 | <1% | 1,352 | $177K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 54,881 | $176K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,305 | $173K |
| 71271 | <1% | 818 | $169K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,321 | $168K |
| 97161 | <1% | 1,999 | $165K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 838 | $161K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 5,382 | $158K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,271 | $155K |
| 76536 | <1% | 1,384 | $153K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,478 | $149K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,509 | $148K |
| 77065 | Tomosynthesis, mammo | <1% | 1,509 | $147K |
| 70498 | <1% | 476 | $141K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,023 | $139K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 881 | $133K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,884 | $132K |
| 73610 | <1% | 2,420 | $132K | |
| 93970 | <1% | 487 | $132K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,414 | $125K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,210 | $117K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,138 | $116K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,977 | $115K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 680 | $114K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,341 | $107K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,006 | $107K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 19 | $101K |
| 80061 | Lipid panel | <1% | 8,082 | $99K |
| 83880 | <1% | 4,340 | $99K | |
| 76818 | <1% | 870 | $99K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 493 | $95K |
| 94060 | <1% | 1,426 | $92K | |
| 73630 | <1% | 1,882 | $91K | |
| 73562 | <1% | 1,366 | $90K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 70 | $89K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,401 | $85K |
| 97597 | <1% | 504 | $84K | |
| 88342 | <1% | 1,802 | $84K | |
| 81513 | <1% | 3,430 | $83K | |
| 73030 | <1% | 1,713 | $81K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,202 | $80K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 562 | $79K |
| 96367 | <1% | 1,027 | $76K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,468 | $73K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,332 | $72K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,079 | $71K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 560 | $68K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 716 | $64K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,779 | $64K |
| 70491 | <1% | 197 | $62K | |
| 72110 | <1% | 609 | $62K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,246 | $62K |
| 73130 | <1% | 1,477 | $61K | |
| 73564 | <1% | 1,335 | $61K | |
| 73110 | <1% | 1,185 | $60K | |
| 74018 | <1% | 1,739 | $59K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,872 | $58K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,743 | $58K |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 95 | $57K |
| 72131 | <1% | 301 | $57K | |
| 97162 | <1% | 658 | $57K | |
| 86850 | <1% | 6,441 | $57K | |
| 70486 | <1% | 250 | $56K | |
| C1769 | Guide wire | <1% | 1,045 | $55K |
| 87088 | <1% | 15,095 | $54K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,916 | $54K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 526 | $53K |
| 96376 | <1% | 2,827 | $53K | |
| 76641 | <1% | 332 | $52K | |
| 88142 | <1% | 2,766 | $52K | |
| 99443 | <1% | 452 | $51K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,032 | $49K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,399 | $49K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,211 | $47K |
| 87481 | <1% | 1,924 | $44K | |
| 58661 | <1% | 12 | $43K | |
| 84702 | <1% | 8,325 | $42K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 361 | $42K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,800 | $41K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 619 | $40K |
| 84484 | <1% | 10,221 | $40K | |
| 96415 | <1% | 244 | $40K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 711 | $40K |
| 82728 | <1% | 3,661 | $40K | |
| 0002A | <1% | 1,100 | $37K | |
| 70496 | <1% | 419 | $37K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 45 | $37K |
| 99223 | Prolong inpt eval add15 m | <1% | 273 | $36K |
| 59050 | <1% | 551 | $35K | |
| 72100 | <1% | 504 | $35K | |
| 0001A | <1% | 1,219 | $34K | |
| 73100 | <1% | 500 | $33K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,121 | $33K |
| 87653 | <1% | 1,270 | $31K | |
| 83735 | <1% | 13,491 | $31K | |
| 77080 | <1% | 258 | $30K | |
| 86480 | <1% | 594 | $30K | |
| 73080 | <1% | 547 | $30K | |
| 90686 | <1% | 2,774 | $29K | |
| 86901 | <1% | 7,160 | $29K | |
| 97166 | <1% | 369 | $29K | |
| 83550 | <1% | 3,580 | $28K | |
| 82607 | <1% | 2,337 | $28K | |
| 86803 | <1% | 3,287 | $28K | |
| 87471 | <1% | 853 | $27K | |
| 87660 | <1% | 2,302 | $25K | |
| 73590 | <1% | 572 | $25K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 418 | $25K |
| 81001 | <1% | 16,868 | $24K | |
| 83655 | <1% | 2,729 | $24K | |
| J3490 | Unclassified drugs | <1% | 250 | $24K |
| 73502 | <1% | 451 | $24K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,397 | $24K |
| 83605 | <1% | 5,934 | $23K | |
| 87510 | <1% | 2,135 | $22K | |
| 87480 | <1% | 2,145 | $22K | |
| 88304 | <1% | 735 | $22K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,775 | $22K |
| 59025 | Fetal non-stress test | <1% | 156 | $22K |
| 85027 | <1% | 5,062 | $22K | |
| 84439 | <1% | 2,876 | $22K | |
| 73140 | <1% | 406 | $22K | |
| 83540 | <1% | 3,942 | $22K | |
| 73090 | <1% | 429 | $22K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 26 | $21K |
| 76870 | <1% | 225 | $21K | |
| 94726 | <1% | 1,047 | $21K | |
| 83690 | <1% | 11,737 | $20K | |
| 0003A | <1% | 498 | $19K | |
| 84703 | <1% | 7,855 | $19K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 445 | $19K |
| 00731 | <1% | 161 | $18K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 347 | $18K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 14 | $18K |
| 12001 | <1% | 184 | $17K | |
| 87186 | <1% | 3,660 | $17K | |
| 99221 | <1% | 208 | $17K | |
| 87340 | <1% | 2,432 | $17K | |
| 93880 | <1% | 93 | $16K | |
| 94729 | <1% | 1,005 | $16K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 28 | $16K |
| 87040 | <1% | 4,789 | $15K | |
| 85610 | <1% | 8,019 | $15K | |
| 81511 | <1% | 142 | $14K | |
| 99442 | <1% | 204 | $14K | |
| 83970 | <1% | 728 | $14K | |
| 87536 | <1% | 174 | $14K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 139 | $14K |
| 98968 | <1% | 438 | $14K | |
| 87077 | <1% | 3,277 | $13K | |
| 0012A | <1% | 408 | $13K | |
| 92557 | <1% | 146 | $13K | |
| 82746 | <1% | 1,125 | $13K | |
| 86592 | <1% | 2,978 | $13K | |
| 0011A | <1% | 578 | $13K | |
| 72081 | <1% | 173 | $13K | |
| 81003 | <1% | 11,615 | $12K | |
| 90715 | <1% | 976 | $12K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,729 | $12K |
| 92523 | <1% | 66 | $12K | |
| 87631 | <1% | 518 | $11K | |
| 86140 | <1% | 5,246 | $11K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 48 | $11K |
| 82962 | <1% | 7,228 | $11K | |
| 99152 | <1% | 346 | $10K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 769 | $10K |
| 85730 | <1% | 4,440 | $10K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 231 | $10K |
| 82077 | <1% | 2,339 | $10K | |
| 01961 | <1% | 42 | $9K | |
| 93925 | <1% | 55 | $9K | |
| 87507 | <1% | 28 | $9K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 513 | $9K |
| 86618 | <1% | 397 | $9K | |
| 87070 | <1% | 1,811 | $9K | |
| 0013A | <1% | 220 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 541 | $8K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,159 | $8K |
| 84403 | <1% | 356 | $8K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 164 | $8K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 484 | $7K |
| 86360 | <1% | 171 | $7K | |
| 72050 | <1% | 123 | $7K | |
| 82570 | <1% | 2,001 | $7K | |
| 86762 | <1% | 1,286 | $7K | |
| 86003 | <1% | 60 | $7K | |
| 83021 | <1% | 861 | $7K | |
| 12011 | <1% | 71 | $7K | |
| 88313 | <1% | 246 | $6K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 69 | $6K |
| 36430 | <1% | 15 | $6K | |
| 84480 | <1% | 517 | $6K | |
| 86787 | <1% | 1,177 | $6K | |
| 82043 | <1% | 1,225 | $6K | |
| 94760 | <1% | 2,530 | $6K | |
| 83615 | <1% | 1,559 | $6K | |
| 97165 | <1% | 96 | $6K | |
| 85018 | <1% | 5,973 | $6K | |
| 86617 | <1% | 187 | $6K | |
| 88341 | <1% | 110 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,549 | $5K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 70 | $5K |
| 72040 | <1% | 109 | $5K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 76 | $5K |
| 82105 | <1% | 460 | $5K | |
| 73560 | <1% | 92 | $5K | |
| 95819 | <1% | 27 | $5K | |
| 86359 | <1% | 171 | $5K | |
| 85379 | <1% | 1,627 | $5K | |
| 86706 | <1% | 504 | $5K | |
| 92550 | <1% | 184 | $5K | |
| 84550 | <1% | 2,381 | $5K | |
| 87503 | <1% | 286 | $5K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 197 | $5K |
| 12002 | <1% | 60 | $5K | |
| 82950 | <1% | 1,042 | $5K | |
| 83020 | <1% | 834 | $5K | |
| 88173 | <1% | 119 | $5K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 130 | $5K |
| 80143 | <1% | 516 | $4K | |
| 88307 | <1% | 53 | $4K | |
| 80179 | <1% | 510 | $4K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 51 | $4K |
| 83001 | <1% | 252 | $4K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 400 | $4K |
| 25600 | <1% | 12 | $4K | |
| 82784 | <1% | 271 | $4K | |
| 96417 | <1% | 76 | $4K | |
| 92567 | <1% | 540 | $4K | |
| 84270 | <1% | 207 | $4K | |
| 81025 | <1% | 653 | $4K | |
| 87205 | <1% | 1,504 | $4K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 62 | $4K |
| 88112 | <1% | 99 | $4K | |
| 82670 | <1% | 148 | $4K | |
| 84402 | <1% | 167 | $4K | |
| 86038 | <1% | 382 | $4K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 548 | $4K |
| 85652 | <1% | 2,132 | $4K | |
| 83002 | <1% | 210 | $3K | |
| 82652 | <1% | 95 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 82 | $3K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 24 | $3K |
| 82803 | <1% | 379 | $3K | |
| 84146 | <1% | 195 | $3K | |
| 0053A | <1% | 83 | $3K | |
| 76937 | <1% | 42 | $3K | |
| 86376 | <1% | 224 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,293 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,388 | $3K |
| 90656 | <1% | 530 | $3K | |
| 80047 | <1% | 652 | $3K | |
| 96160 | <1% | 775 | $3K | |
| 84153 | <1% | 167 | $2K | |
| 0099U | <1% | 77 | $2K | |
| 10060 | <1% | 13 | $2K | |
| 86704 | <1% | 216 | $2K | |
| 84100 | <1% | 2,259 | $2K | |
| 82248 | <1% | 507 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,268 | $2K |
| 0031A | <1% | 57 | $2K | |
| 80076 | <1% | 311 | $2K | |
| 97167 | <1% | 25 | $2K | |
| 90677 | <1% | 300 | $2K | |
| 86703 | <1% | 141 | $2K | |
| 84520 | <1% | 2,877 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 600 | $2K |
| 86709 | <1% | 249 | $2K | |
| 86765 | <1% | 187 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,229 | $2K |
| 96368 | <1% | 114 | $2K | |
| 97803 | <1% | 95 | $2K | |
| 82550 | <1% | 644 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,668 | $2K |
| 86705 | <1% | 234 | $2K | |
| 83516 | <1% | 106 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,807 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 549 | $1K |
| 86430 | <1% | 271 | $1K | |
| 82945 | <1% | 107 | $1K | |
| A4657 | Syringe, with or without needle, each | <1% | 10,928 | $1K |
| 29125 | <1% | 26 | $1K | |
| 86780 | <1% | 108 | $1K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $1K |
| 97802 | <1% | 73 | $1K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 422 | $1K |
| 73000 | <1% | 16 | $1K | |
| 86364 | <1% | 118 | $1K | |
| 87338 | <1% | 100 | $1K | |
| 84156 | <1% | 690 | $1K | |
| 72170 | <1% | 42 | $1K | |
| 86735 | <1% | 126 | $1K | |
| 99381 | <1% | 12 | $1K | |
| C1819 | Surgical tissue localization and excision device (implantable) | <1% | 154 | $1K |
| 92579 | <1% | 12 | $1K | |
| D1110 | Prophylaxis - adult | <1% | 5,891 | $1K |
| 73070 | <1% | 14 | $1K | |
| 86308 | <1% | 311 | $1K | |
| 98967 | <1% | 43 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,455 | $946.22 |
| 82040 | <1% | 271 | $904.70 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 422 | $897.22 |
| 84145 | <1% | 301 | $874.54 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,823 | $873.03 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $854.96 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 27 | $839.09 |
| 82247 | <1% | 190 | $817.81 | |
| 84436 | <1% | 137 | $805.45 | |
| 11719 | <1% | 28 | $800.00 | |
| 82150 | <1% | 135 | $790.39 | |
| C1788 | Port, indwelling (implantable) | <1% | 12 | $768.51 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,480 | $748.34 |
| 71101 | <1% | 29 | $737.32 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 636 | $734.25 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 82 | $706.47 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 413 | $704.18 |
| 73552 | <1% | 15 | $693.98 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 78 | $686.73 |
| 92610 | <1% | 13 | $680.42 | |
| 99441 | <1% | 27 | $675.69 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 530 | $649.61 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 70 | $640.60 |
| 82948 | <1% | 552 | $608.44 | |
| 87430 | <1% | 181 | $606.79 | |
| 0052A | <1% | 15 | $578.86 | |
| 87899 | <1% | 143 | $569.62 | |
| 84481 | <1% | 41 | $568.28 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,116 | $568.18 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,486 | $552.62 |
| D0120 | Dental checkup, returning patient | <1% | 8,499 | $551.00 |
| 96127 | <1% | 151 | $538.39 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,562 | $537.35 |
| 90474 | <1% | 90 | $535.50 | |
| 87800 | <1% | 14 | $524.76 | |
| 97116 | <1% | 31 | $522.58 | |
| 0034A | <1% | 13 | $510.48 | |
| 0051A | <1% | 13 | $501.88 | |
| 94010 | <1% | 19 | $499.87 | |
| 82951 | <1% | 40 | $488.26 | |
| 99078 | <1% | 16 | $480.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 268 | $453.93 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 624 | $435.34 |
| 96130 | <1% | 13 | $428.68 | |
| 87517 | <1% | 12 | $427.28 | |
| 87469 | <1% | 13 | $423.53 | |
| 86769 | <1% | 14 | $421.30 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 94 | $415.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,098 | $409.44 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 65 | $407.24 |
| 90480 | <1% | 46 | $405.75 | |
| 87420 | <1% | 104 | $396.90 | |
| 81015 | <1% | 380 | $384.02 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 17 | $373.01 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 862 | $370.54 |
| D0140 | Limited oral evaluation - problem focused | <1% | 4,856 | $362.11 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 138 | $355.98 |
| A4649 | Surgical supply; miscellaneous | <1% | 63 | $310.92 |
| 73060 | <1% | 13 | $304.93 | |
| 87484 | <1% | 13 | $299.60 | |
| 87468 | <1% | 13 | $299.60 | |
| 87478 | <1% | 13 | $299.60 | |
| D0274 | Bitewings - four radiographic images | <1% | 3,631 | $290.00 |
| 82627 | <1% | 12 | $279.05 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 873 | $276.10 |
| 88302 | <1% | 12 | $271.46 | |
| D2330 | <1% | 406 | $262.50 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $255.46 |
| D0220 | Intraoral - periapical first radiographic image | <1% | 4,652 | $253.31 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $250.16 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 573 | $248.62 |
| 90662 | <1% | 126 | $247.62 | |
| 86696 | <1% | 17 | $225.22 | |
| 85045 | <1% | 76 | $216.80 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,072 | $210.46 |
| D0330 | Panoramic radiographic image | <1% | 2,745 | $200.00 |
| 82747 | <1% | 12 | $192.31 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 118 | $187.68 |
| 93000 | <1% | 13 | $182.38 | |
| C1758 | Catheter, ureteral | <1% | 13 | $180.19 |
| 81002 | <1% | 44 | $178.98 | |
| 92555 | <1% | 13 | $177.18 | |
| 86923 | <1% | 46 | $172.49 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 45 | $170.59 |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 2,692 | $168.00 |
| 86695 | <1% | 17 | $161.23 | |
| G0008 | Administration of influenza virus vaccine | <1% | 240 | $160.99 |
| 80320 | <1% | 41 | $153.58 | |
| 86225 | <1% | 12 | $139.52 | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 1,599 | $120.00 |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 2,798 | $119.00 |
| 36410 | <1% | 15 | $115.68 | |
| 83695 | <1% | 13 | $113.82 | |
| 82947 | <1% | 29 | $113.69 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 127 | $113.29 |
| 92700 | <1% | 20 | $102.95 | |
| 82952 | <1% | 28 | $95.20 | |
| D2331 | <1% | 45 | $87.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 127 | $82.23 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 320 | $75.41 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 36 | $72.74 |
| 90473 | <1% | 14 | $70.00 | |
| 82009 | <1% | 74 | $68.42 | |
| 99173 | <1% | 1,781 | $65.42 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,828 | $61.14 |
| 82565 | <1% | 12 | $61.11 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 50 | $57.63 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 116 | $53.88 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 99 | $52.97 |
| Q3014 | Telehealth originating site facility fee | <1% | 60 | $51.71 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 582 | $50.12 |
| 84132 | <1% | 28 | $45.22 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 80 | $44.56 |
| 83721 | <1% | 12 | $34.06 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 18 | $24.80 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 60 | $24.18 |
| 90785 | <1% | 18 | $23.79 | |
| J1815 | Injection, insulin, per 5 units | <1% | 318 | $19.32 |
| D0272 | Bitewings - two radiographic images | <1% | 1,783 | $17.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 59 | $11.16 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 25 | $10.86 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 52 | $10.54 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 14 | $9.29 |
| 99001 | <1% | 13 | $6.27 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 76 | $6.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 56 | $2.58 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 36 | $2.09 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,947 | $0.33 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 39 | $0.18 |
| 90619 | <1% | 66 | $0.11 | |
| D2393 | Resin-based composite - three surfaces, posterior, primary or permanent | 0% | 204 | $0.00 |
| D1208 | Topical application of fluoride, excluding varnish | 0% | 3,946 | $0.00 |
| 90651 | 0% | 54 | $0.00 | |
| D1206 | Topical application of fluoride varnish | 0% | 1,044 | $0.00 |
| D1330 | 0% | 1,019 | $0.00 | |
| 90680 | 0% | 63 | $0.00 | |
| 90697 | 0% | 79 | $0.00 | |
| 96131 | 0% | 13 | $0.00 | |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | 0% | 13 | $0.00 |
| D1120 | Dental cleaning, child | 0% | 3,718 | $0.00 |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | 0% | 3,269 | $0.00 |
| D0270 | 0% | 333 | $0.00 | |
| 90734 | 0% | 27 | $0.00 | |
| 91320 | 0% | 25 | $0.00 | |
| 85007 | 0% | 12 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWHITE, CODY (AVP REVENUE CYCLE SERVICES)
| Provider | Location | Paid |
|---|---|---|
| MVHS INC | Utica, NY | $1.98M |
| ST Luke's Home Residential Health Care Facility INC | Utica, NY | $139K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.